An anti-alpha-fetoprotein (AFP) CAR-T has shown potent anti-tumor activity in vivo in mouse models [44], and a Phase I clinical trial has been conducted in patients with AFP+ HCC, the results of which are not yet available (NCT03349255). This evidence concerns the gene AFP and neoplasm.